In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akorn Inc.

www.akorn.com

Latest From Akorn Inc.

Akorn Reports ‘Sustained’ Progress On FDA Issues

Beleaguered niche generic drugmaker Akorn has reported stronger-than-expected first-quarter earnings and says it is making progress on resolving FDA-related compliance problems.

Sales & Earnings Strategy

Widespread Off-Label Use Could Ensure Injectable Bacitracin's Future

US FDA advisory committee will weigh fate of the injectable antibiotic, which can cause renal failure and is only approved for treatment of pediatric pneumonia. However, its real-world use is almost entirely in the surgical setting for irrigation and prophylaxis. Xellia, one of five companies that markets the generic drug, said the risk/benefit profile for on-label use remains positive and evidence on off-label use warrants further exploration.

Advisory Committees Drug Review

Sun Hopes Cequa’s Nano Formulation Makes Big Impact

Sun’s now-approved higher concentration, quicker-acting formulation of cyclosporine A could offer competitive advantage in dry eye versus Allergan’s Restasis, but is it enough to offset lower costs of pending generic cyclosporines?

Approvals Business Strategies

The Quality Lowdown: EU/Japan MRA, Field Alerts, Akorn, New Pfizer Plant, And The Answer Is Continuous Manufacturing

Japan and EU expand drug inspection agreement while rebuking Trump on trade; Pfizer invests tax cut in modular plant; FDA commissioner sells continuous manufacturing.

Quality Compliance
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
    • Radiopharmaceuticals, Contrast Agents
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Akorn Inc.
  • Senior Management
  • Raj Rai, CEO
    Duane A Portwood, CFO
    Jonathan Kafer, EVP, Sales & Mktg.
    Bruce Kutinsky, PharmD, COO
    Steve Lichter, EVP, Pharma Ops
    Randall E Pollard, Chief Accounting Officer
  • Contact Info
  • Akorn Inc.
    Phone: (800) 932-5676
    1925 West Field Ct.
    Ste. 300
    Lake Forest, IL 60045
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register